赛伦生物12月24日获融资买入150.98万元，融资余额1.59亿元

Group 1 - The core viewpoint of the news is that Sairun Bio has shown stable financial performance with slight growth in revenue and net profit, while also experiencing significant activity in its financing and margin trading [1][2]. Group 2 - As of December 24, Sairun Bio's stock price increased by 0.36%, with a trading volume of 9.55 million yuan. The financing buy-in amount for the day was 1.51 million yuan, while the financing repayment was 1.27 million yuan, resulting in a net financing buy-in of 236,400 yuan [1]. - The total balance of margin trading for Sairun Bio reached 159 million yuan, accounting for 6.65% of its market capitalization, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1]. - On the short-selling side, there were no shares repaid or sold on December 24, with the short-selling balance also at zero, reflecting a high level of inactivity in this area [1]. Group 3 - As of September 30, the number of shareholders for Sairun Bio was 6,635, a decrease of 14.1% from the previous period. The average number of circulating shares per person increased to 16,310 shares, up by 183.92% [2]. - For the period from January to September 2025, Sairun Bio reported a revenue of 175 million yuan, representing a year-on-year growth of 1.07%. The net profit attributable to the parent company was 64.21 million yuan, with a year-on-year increase of 2.01% [2]. - Since its A-share listing, Sairun Bio has distributed a total of 248 million yuan in dividends, with 150 million yuan distributed over the past three years [2].